14
Expanded Portfolio for Biomolecules Purifi cation Announced
With the increased interest in the purifi cation of a wider variety of biomolecules, the portfolio of Kromasil 300 Å has been expanded to support these applications.
The Kromasil 300 Å line of HPLC products is now shipping with C18, C8, C4 and diC4 derivatisations for scientists and engineers exploiting selectivity and loadability for purifi cation of API and impurity isolation. In particular, the new Kromasil 300 Å diC4 has different characteristic than a classic C4, enabling new opportunities to remove impurities from peptide and protein crudes.
For more information, visit
www.kromasil.com.
44181pr@reply-direct.com
New Protein A
Chromatography Resin Increases Monoclonal Antibody Purifi cation by up to 40%
GE Healthcare introduces a new Protein A chromatography resin, MabSelect PrismA, which will help biopharmaceutical manufacturers improve their monoclonal antibody (mAb) purifi cation capacity by up to 40%. The resin is also signifi cantly more alkaline-stable, meaning that MabSelect PrismA can be cleaned with a higher concentration of sodium hydroxide to better control cross- contamination and bioburden risks.
24th - 26th January 2018, Cardiff, UK 15th International Symposium on
Hyphenated Techniques in Chromatography and Separation Technology
HTC 15 will take place in the historic city of Cardiff and will cover all fundamental aspects, instrumental developments and applications of hyphenated chromatography techniques. These include hyphenation between chromatography and new detection systems, multi column (multi-dimensional) chromatography, and the coupling between sample preparation and separation techniques. Many aspects of chromatography are addressed, including automation, miniaturisation, and micro fabricated analytical devices, high pressure and high temperature LC.
Besides the core scientifi c programme, the symposium will host an attractive technical exhibition where companies active in the fi eld will present their latest developments in instrumentation, software and applications related to the hyphenation of separation, detection and sample preparation techniques topped with technical seminars.
MabSelect PrismA addresses a number of key challenges, including the increased upstream titers. The new resin is highly effi cient due to its excellent binding capacity, which is critical, because it determines how much resin is needed to purify a certain amount of protein.
“Biopharma companies are constantly looking for more ways to increase their output, and Protein A has a critical role to support these efforts. The thorough research and development work that we have carried out to create MabSelect PrismA sets a new standard for mAb purifi cation. To put it simply, with this chromatography resin our customers will be able to produce more biopharmaceuticals out of their existing manufacturing equipment. Protein purifi cation is no longer a bottleneck, but driving higher productivity and shorter manufacturing lead times for our customers,” said Jan Makela, General Manager, BioProcess, GE Healthcare Life Sciences.
MabSelect PrismA has been developed at the GE Healthcare Life Sciences site in Uppsala, Sweden, where the resin is also manufactured. The factory in Uppsala is one of the largest manufacturing facilities for chromatography resins in the world, and between 2017 and 2022 GE is annually investing up to USD 70 million in the production facility to signifi cantly increase its capacity.
44304pr@reply-direct.com
Online advertising with proven results...
www.ilmexhibitions.com/HTC Tel: +44 (0) 1727 858840 • Email:
Info@ilmexhibitions.com
Supporting Organisations:
www.labmate-online.com ...try out our new website.
HTC
210x275.indd 1 08/11/2017 12:11
LAB ASIA - NOVEMBER/DECEMBER 2017
REGISTRATION NOW OPEN
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
